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Background
A prompt and effective diagnosis and a timely treatment
of atypical mycobacteriosis, and especially Mycobacterium
kansasii, Mycobacterium xenopi, and Mycobacterium
fortuitum disease, remains a serious challenge for clini-
cians engaged in the management of the immunocompro-
mised host, including HIV disease.
Methods
Eighteen, twelve, and three HIV-infected patients with a
microbiologically-confirmed M. kansasii, M. xenopi, and
M. fortuitum respiratory infection respectively, have
been observed in a 16-year period, out of over 4,700
hospitalizations performed because of HIV-associated
disorders at our inpatient centre. These episodes were
carefully evaluated from an epidemiological, bacteriolo-
gical, clinical, and therapeutic point of view.
Results
In 15 out of the 33 overall episodes (45.5%), a concurrent
bacteremia was also retrieved, as a sign of disseminated
infection. A rapid and significant reductin of the crude fre-
quency of atypical mycobacteriosis as a major HIV-related
complication, occurred shortly after the introduction of
potent antiretroviral combinations (cART) in the year
1996. In fact, until early nineties, the lack of potent antire-
troviral regimens made frequent the association of
this opportunism with full-blown AIDS, a mean CD4+
lymphocyte count of around 20-50 cells/μL, and extremely
variable chest X-ray features and systemic presentations.
The recent detection of 9 further episodes of atypical
mycobacteriosis in the year 2009 was due to a late recogni-
tion of a far advanced HIV disease (the so-called “AIDS
presenters”), which were already complicated by multiple
opportunistic disorders.
Discussion
M. kansasii, M. xenopi, and M. fortuitum respiratory
and/or disseminated infection continues to occur, and
pose relevant diagnostic problems, including late or
missed identification due to slow culture and frequently
concurrent opportunistic disease. Serious therapeutic
difficulties, due to the unpredictable in vitro antimicro-
bial susceptibility profile of these organisms, and the
need to start as soon as possible an effective combina-
tion therapy which should not interfere with other med-
ications (especially cART), are also of concern.
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